

**Table S1** Feasibility of the perioperative concepts in published clinical trials

Trial	≥3 cycles of neoadjuvant therapy (% patients)	Surgery (% patients)	R0 (% surgery)	Started adjuvant therapy (% patients)	Discontinued adjuvant therapy (% patients)	Pneumonectomy (% patients)
Keynote-671	87.4	82.1	92.0	73.0	-34.0	11.4
AEGEAN	84.7 <sup>†</sup>	80.6	91.2	66.0	-43.5	7.4
Checkmate-77T	85.0	78.0	89.0	62.0	-34.0	8.9
Neotorch	87.1	82.2	95.8	71.0	-27.0	9.0
Rationale-315	91.6	84.1	NR	NR	NR	NR
NADIM-2	94.0	92.9	94.3	73.6	-21.4	10.5
Average	88.3	83.3	92.5	69.2	-32.0	9.4
95% CI	84.4–92.2	78.0–88.7	89.2–95.8	63.0–75.4	-21.6 to -42.3	7.5–11.4

The percentage of patients completing each step of perioperative therapy according to the published results from the experimental arms of Keynote-671, AEGEAN, Neotorch, Checkmate-77T, Rationale-315 and NADIM-2 trials (*Table 1*). The values of this table were used to prepare *Figure 2*. <sup>†</sup>, for the AEGEAN trial only data about completion of 4 neoadjuvant cycles available. CI, confidence interval; NR, not reported as of November 2023.